<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01303042</url>
  </required_header>
  <id_info>
    <org_study_id>AGU-247</org_study_id>
    <nct_id>NCT01303042</nct_id>
  </id_info>
  <brief_title>Efficacy of Insulin Lispro Mix 50/50 Therapy</brief_title>
  <official_title>Multicenter Trial on Clinical Utility of Insulin Lispro Mix 50/50 T.I.D. Therapy in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aichi Gakuin University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aichi Gakuin University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insulin therapy with lispro mix 50/50 t.i.d. is a treatment with a single insulin device. The
      management is comparatively simple and easy, but the curative effect is promising. It is also
      reported that noninferiority has been observed between basal/bolus therapy (BBT) and prandial
      premixed therapy (PPT, lispro mix 50/50 t.i.d.).

      The purpose of this study is to evaluate whether change of insulin therapy from BBT
      (long-acting insulin at bedtime plus mealtime rapid-acting insulin) or analog insulin therapy
      t.i.d. (including therapies with aspart mix 70/30 and lispro mix 75/25) to lispro mix 50/50
      t.i.d. improves glycemic control of patients with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will continue existing insulin therapy for three months. After that, the
      investigators will change insulin therapy according to the insulin regimen below and continue
      the therapy for six months.

      Patients will terminate from sulfonylurea treatment at the change of insulin therapy. The
      investigators will not change other oral hypoglycemic agents during the whole study period.

      Regimen: Divide the total units of all insulin per day by three and equally apply the amount
      to mealtime injections of insulin lispro mix 50/50 t.i.d. When the unit is indivisible and
      the remainder is one unit, add it to the mealtime injection of breakfast. When the remainder
      is two units, add each unit to mealtime injections of breakfast and dinner.

      Patients will terminate from the trial when their HbA1c increases by 1% and stays at the
      level for more than three months after the change of insulin regimen.

      When there is a risk of hypoglycemia at the change of insulin regimen, the investigators will
      divide ninety percent of the total insulin units per day by three and equally apply the
      amount to mealtime injections of insulin lispro 50/50. When considered to be safe, the
      investigators will increase the insulin unit per day to the total insulin unit at the
      previous treatment within two months.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pre- and postprandial glucose levels in SMBG</measure>
    <time_frame>nine months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total score of Questionnaire on QOL</measure>
    <time_frame>nine months</time_frame>
    <description>Secondary end points include change in HbA1c and rates of hypoglycemia.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Insulin lispro mix 50/50</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin lispro mix 50/50</intervention_name>
    <description>Insulin lispro mix 50/50 t.i.d : six months</description>
    <arm_group_label>Insulin lispro mix 50/50</arm_group_label>
    <other_name>Humalog Mix 50/50</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Type 2 diabetes patients who are treated with insulin basal/bolus therapy ( long-acting
        insulin at bedtime and mealtime rapid-acting insulin ) or analog insulin therapy t.i.d.
        (including therapies with aspart mix 70/30 and lispro mix 75/25) and whose HbA1c is above
        7.4%.

        Exclusion Criteria:

          -  Patients with renal failure with serum creatinine level â‰§ 2.0

          -  Patients with hepatocirrhosis

          -  Patients with proliferative diabetic retinopathy or worse

          -  Patients with acute infectious disease

          -  Patients who are treated with steroids

          -  Patients with cancer

          -  Pregnant patients

          -  Patients who are decided to be inappropriate subjects by study physicians
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takahiro Tosaki, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Intern. Med., School of Dentistry, Aichi Gakuin University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takahiro Tosaki, MD, PhD</last_name>
    <phone>+81-52-759-2111</phone>
    <email>nrd49075@nifty.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dept. of Intern. Med., School of Dentistry, Aichi Gakuin University</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takahiro Tosaki, MD, PhD</last_name>
      <phone>+81-52-759-2111</phone>
      <email>nrd49075@nifty.com</email>
    </contact>
    <investigator>
      <last_name>Takahiro Tosaki, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Keiko Naruse, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tosaki Clinic for Diabetes and Endocrinology</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>468-0009</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Takahiro Tosaki, MD, PhD</last_name>
      <email>nrd49075@nifty.com</email>
    </contact>
    <investigator>
      <last_name>Takahiro Tosaki, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diabetes Clinic, Okazaki East Hospital</name>
      <address>
        <city>Okazaki</city>
        <state>Aichi</state>
        <zip>444-0008</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takahiro Tosaki, MD, PhD</last_name>
      <phone>+81-564-22-6616</phone>
      <email>nrd49075@nifty.com</email>
    </contact>
    <investigator>
      <last_name>Chizuko Suzuki, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maiko Mizutani, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Takahiro Tosaki, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diabetes Center, Yokkaichi Social Insurance Hospital</name>
      <address>
        <city>Yokkaichi</city>
        <state>Mie</state>
        <zip>510-0016</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takahiro Tosaki, MD, PhD</last_name>
      <phone>+81-59-331-2000</phone>
      <email>nrd49075@nifty.com</email>
    </contact>
    <investigator>
      <last_name>Miho Miyoshi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tomoki Majima, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Takahiro Tosaki, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2011</study_first_submitted>
  <study_first_submitted_qc>February 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2011</study_first_posted>
  <last_update_submitted>February 23, 2011</last_update_submitted>
  <last_update_submitted_qc>February 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>Takahiro Tosaki</name_title>
    <organization>Aichi Gakuin University</organization>
  </responsible_party>
  <keyword>insulin LISPRO</keyword>
  <keyword>Insulin therapy</keyword>
  <keyword>hemoglobin A1c protein, human</keyword>
  <keyword>Blood Glucose Self-Monitoring</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Hypoglycemia</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>1,5-Anhydroglucitol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

